Stock Analiz

Relmada Therapeutics, Inc. (RLMD) stock forecast and price target

Price $4.21 · data as of November 13, 2026

12-month price target

Average target$10.75
Upside / downside+155.3%
Analysts4
ConsensusStrong buy
Low $9.00Average $10.75High $12.00

Gold marker: average target · white marker: today’s price ($4.21)

Analyst ratings

Strong buy 1Buy 3Hold 0Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-0.41+62.8%$0
Next fiscal year
ends December 31, 2027
$-0.41+0.0%$0
Next quarter
ends December 31, 2026
$-0.12—$0
Quarter after
ends March 31, 2027
$-0.14—$0

Consensus of the analysts covering Relmada Therapeutics, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.

Frequently asked questions

What is the Relmada Therapeutics stock price target?

The average 12-month target from 4 analysts is $10.75, 155.3% above the current price of $4.21 Targets range from $9.00 to $12.00.

Is Relmada Therapeutics a buy according to analysts?

The consensus rating is “Strong buy” (1 strong buy, 3 buy). Ratings are opinions, not guarantees; this is not investment advice.

How much is Relmada Therapeutics expected to earn?

Analysts expect EPS of $-0.41 for the fiscal year ending December 31, 2026 and $-0.41 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.